Efficacy and safety of fuzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: A multi-center, single-arm prospective phase II clinical study (STAMP study)

Small-cell lung cancer (SCLC) is a highly aggressive and lethal malignancy that accounts for 10–15% of lung cancers, and it is generally divided into limited and extensive stage. The standard of care for patients with newly diagnosed extensive-stage SCLC (ES-SCLC) is still platinum-based chemotherapy and as maintenance therapy scheme.